fda warning compounding semaglutide september 2025 Diabetes advocacy group discourages use of compounded GLP-1 drugs US FDA removes suicidal thoughts

however, those who persisted with the medication coverage experienced weight losses comparable with those shown in corresponding clinical trials. And in a paper published in 2023, researchers found that while significant weight loss was achievable with GLP-1s among type 2 diabetes patients, the average weight reduction was relatively modest, 2.2% after 72 weeks of being on the medications

The increased sympathetic tone may explain a known GLP-1RA class effect of a modest but significant increase in heart rate, the clinical consequences of which are undetermined

Herbs and dietary supplements in the prevention and treatment of cardiovascular disease

Therefore, it seems obvious that weight loss eases osteoarthritis by reducing load-bearing forces on the joints